E. Garrett Ingram is a leading biotech executive with extensive expertise in global medicines and market access. She joined Cipla in June 2019 as Chief Commercial Officer and Head of Cipla Therapeutics, driving the transformation of biotech and specialty platforms. With over twenty years of experience in pharmaceuticals, biotech, and device marketing, Garrett has a proven track record of leadership, successfully guiding organizations through turnarounds and delivering profitability.
In July 2020, Garrett was appointed President & CEO of Cipla Therapeutics, Inc., leading the institutional specialty business. In 2023, she was named one of the Top 25 Healthcare Technology Leaders of NJ. Before Cipla, she served as Chief Marketing Officer at MannKind Corporation, delivering share and net profit growth and leading strategies for new compounds and brand plans.
Garrett has held senior roles at Dexcom, Sanofi, Bristol Myers Squibb, and Novo Nordisk, where she led market access strategies, managed launches, and developed innovative partnerships like the Diabetes Prevention and Control Alliance. She has extensive experience in marketing, launch, managed care, health economics, and multi-product lifecycle management with Pfizer, Pharmacia/Upjohn, and healthcare provider organizations.
Garrett holds a Bachelor of Science degree from East Carolina University and a master's degree in public health from the University of South Carolina. She has completed executive leadership programs at Wharton School of Business and dedicates her free time to mentorship and community impact. She is currently a board member of Alveus Therapeutics and Cipla Therapeutics, Inc.